Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

Key Points

• Wedbush lowered its BioCryst price target from $18 to $17 but maintained an “outperform” rating; the new target implies 106.31% upside from the prior close.
• Analyst sentiment is mixed but leans positive: six analysts rate the stock Buy, two Hold, and one Sell. MarketBeat’s consensus is “Moderate Buy” with a $20.38 price target.
• BioCryst beat quarterly estimates, reporting EPS of $0.14 versus $0.09 expected and revenue of $180.29 million versus $165.67 million; revenue increased 13.1% year over year.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its price target dropped by equities researchers at Wedbush from $18.00 to $17.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the biotechnology company's stock. Wedbush's price objective indicates a potential upside of 106.31% from the company's previous close.

A number of other brokerages have also weighed in on BCRX. Needham & Company LLC reiterated a "buy" rating and set a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Wednesday, September 30th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, October 24th. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a "hold (c)" rating to a "sell (d-)" rating in a report on Tuesday, September 22nd. Finally, Royal Bank Of Canada downgraded shares of BioCryst Pharmaceuticals from an "outperform" rating to a "sector perform" rating and cut their price objective for the stock from $13.00 to $11.00 in a report on Thursday, September 10th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $20.38.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $8.24 on Thursday. The stock has a market capitalization of $2.11 billion, a PE ratio of -5.49 and a beta of 0.55. BioCryst Pharmaceuticals has a one year low of $6.23 and a one year high of $11.22. The business's fifty day moving average price is $8.55 and its 200-day moving average price is $8.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $180.29 million during the quarter, compared to analyst estimates of $165.67 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The firm's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.06 EPS. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -2.28 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth approximately $238,930,000. Jupiter Topco LLC bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at approximately $95,268,000. Janus Henderson Group PLC lifted its position in BioCryst Pharmaceuticals by 20.3% during the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company's stock valued at $84,854,000 after purchasing an additional 1,504,120 shares during the last quarter. Perceptive Advisors LLC lifted its position in BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company's stock valued at $70,772,000 after purchasing an additional 4,271,504 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in BioCryst Pharmaceuticals by 231.6% in the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company's stock worth $48,474,000 after buying an additional 3,556,208 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals News Summary

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: BioCryst reported Q3 adjusted earnings of $0.14 per share, above the roughly $0.09 analyst consensus, and revenue of $180.29 million versus estimates of $165.67 million. Revenue rose 13.1% year over year. BioCryst Reports Third Quarter 2026 Financial Results
• Positive Sentiment: A report on the quarter says the company raised its guidance, while earnings-call coverage highlighted continued growth in ORLADEYO, its hereditary angioedema treatment. These updates support the outlook for the business. BioCryst Pharma Q3 2026: Revenue Beats and Guidance Raised BioCryst Earnings Call Highlights ORLADEYO Growth
• Neutral Sentiment: Although the reported results and guidance were favorable, the available articles do not explain why shares came under pressure. The decline may reflect market expectations or trading factors, but the reports do not establish a cause.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst's primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.